 |
|
|
| |
Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma: Survival, Hepatic Safety, and Biomarker Assessments in CheckMate-040
|
| |
| |
Reported by Jules Levn
The Liver Meeting, American Association for the Study of Liver Diseases (AASLD 2017)Washington, DC, October 20-24, 2017
Bruno Sangro,1Ignacio Melero,2,3Thomas Yau,4ChiunHsu,5Masatoshi Kudo,6Tae-You Kim,7Su-Pin Choo,8JörgTrojan,9Theodore H. Welling, III,10Tim Meyer,11Yoon-Koo Kang,12Winnie Yeo,13AkhilChopra,14Adyb Baakili,15Christine delaCruz,15Huanyu Zhao,15Jaclyn Neely,15Todd S. Crocenzi,16Anthony B. El-Khoueiry17
1Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain;2Clínica Universidad de Navarra and CIBERONC, Pamplona, Spain; 3Center for Applied Medical Research (CIMA), Pamplona, Spain; 4University of Hong Kong, Hong Kong, China; 5National Taiwan University Hospital, Taipei, Taiwan; 6Kindai University Faculty of Medicine, Osaka, Japan; 7Seoul National University Hospital, Seoul, Korea; 8National Cancer Center, Singapore; 9Goethe University Hospital and Cancer Center, Frankfurt, Germany; 10New York University LangoneHealth, New York, NY, USA; 11Royal Free Hospital, London, UK; 12Asan Medical Center, University of Ulsan, Seoul, Korea; 13Chinese University of Hong Kong, Hong Kong, China; 14Johns Hopkins Singapore International Medical Centre, Singapore, Singapore; 15Bristol-Myers Squibb, Princeton, NJ, USA;16Providence Cancer Center, Portland, OR, USA; 17USC Norris Comprehensive Cancer Center, Los Angeles, CA, USA
|
| |
|
|
|
|
|
